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Myeloperoxidase (MPO) is one of the major target antigens of
antineutrophil cytoplasmic autoantibodies (ANCA) found in
patients with small-vessel vasculitis and pauci-immune
necrotizing glomerulonephritis. To date, the target epitopes
of MPO-ANCA remain poorly defined. Human MPO-ANCA do
not typically bind mouse MPO. We utilized the differences
between human and mouse MPO to identify the target
regions of MPO-ANCA. We generated five chimeric MPO
molecules in which we replaced different segments of the
human or mouse molecules with their homologous
counterpart from the other species. Of serum samples from
28 patients screened for this study, 43 samples from 14
patients with MPO-ANCA-associated vasculitis were tested
against recombinant human and mouse MPO and the panel
of chimeric molecules. Sera from 64 and 71% of patients
bound to the carboxy-terminus of the heavy chain, in the
regions of amino acids 517–667 or 668–745, respectively. No
patient serum bound the MPO light chain or the amino-
terminus of the heavy chain. All sera bound to only one or
two regions of MPO. Although the pattern of MPO-ANCA
binding changed over time (4–27 months) in 6 of 10 patients
with several serum samples, such changes were infrequent.
Other target regions of MPO-ANCA may not have been
detected due to conformational differences between the
native and recombinant forms of MPO. MPO-ANCA do not
target a single epitope, but rather a small number of regions
of MPO, primarily in the carboxy-terminus of the heavy chain.
Kidney International (2006) 69, 1799–1805. doi:10.1038/sj.ki.5000354;
published online 22 March 2006
KEYWORDS: vasculitis; ANCA; myeloperoxidase; epitope; glomerulonephritis
Knowledge about the target epitopes of autoantibodies
can provide valuable insight into the mechanisms that
initiate and regulate the autoimmune response. Epitope
mapping can identify molecular mimics and elucidate
the relationship between an alloantigen and autoimmune
disease. The analysis of changes in target epitopes over time
in an individual patient may also provide insight as to
whether relapses are associated with reactivity to a new
epitope or reactivation of an antibody response to the same
epitope(s).
Antineutrophil cytoplasmic autoantibodies (ANCA) di-
rected against myeloperoxidase (MPO) or proteinase 3 are
associated with pauci-immune necrotizing and crescentic
glomerulonephritis, microscopic polyangiitis, and Wegener’s
granulomatosis.1 To date, the epitope specificity of MPO-
ANCA remains poorly defined. Characterizations of the
MPO-ANCA epitope specificity performed by analysis of
competitive binding of various antibodies or antisera to
MPO2–4 or by analysis of binding to various fragments5 or
synthetic overlapping peptides6 of MPO have led to
inconclusive results. Furthermore, methods utilizing protein
fragments or peptides fail to ‘present’ candidate target
epitopes in a preserved three-dimensional conformation.
Finally, very limited information is available as to whether the
same epitopes are targeted during the onset of disease and
relapse.7
Chimeric molecules have been used to determine the
immunodominant epitopes of several autoantigens such as
thyroid peroxidase8 and the glomerular basement mem-
brane’s non-collagenous domain 1 (NC1) domain of the
alpha 3 chain of type IV collagen.9 Despite an 85% amino-
acid identity (90% homology) between the human and
mouse MPO sequences (Figure 1), the majority of human
MPO-ANCA do not bind mouse MPO. We hypothesized that
the areas of heterogeneity between human and mouse MPO
are candidate target epitopes for MPO-ANCA. Furthermore,
we hypothesized that the anti-MPO autoimmune response is
directed against a limited number of immunodominant
epitopes on MPO and that the same epitopes are targeted
during disease onset and relapse.
We exploited the difference in ANCA reactivity to human
and mouse MPO to identify immunodominant epitopes of
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human MPO using a panel of recombinant human MPO,
recombinant mouse MPO, and five human–mouse chimeric
molecules. This approach allows presentation of selected
regions of MPO in a preserved three-dimensional configura-
tion. Chimeric molecules were designed to present a region of
human MPO on the framework of the mouse MPO molecule.
If this human region contains the target epitope of an MPO-
ANCA, the antibody binding to the chimeric would be
greater than that binding to recombinant mouse MPO.
Alternatively, chimeric molecules were generated by replacing
a region of the human MPO molecule by its homologous
region from mouse MPO. If that region contains the target
epitope, the antibody binding to the chimeric would be less
than that binding to recombinant human MPO.
RESULTS
Generation of chimeric molecules
The heavy chain of MPO was ‘divided’ into four segments,
namely A, B, C, and D (Figure 2). We used capital letters to
denote a human segment and lower-case letters to denote a
mouse segment. ‘L’ or ‘l’ denotes the MPO light chain.
Human and mouse recombinant MPO and five of the six
chimeric MPO molecules (full description in Materials and
Methods) were successfully expressed in human embryonic
kidney 293 cells and the purified recombinant proteins
verified by Western blot analysis (Figure 3). We were unable
to express the ‘labcD’ despite three transfections of human
embryonic kidney 293 cells. For each construct, we detected
bands of 70 and 90 kDa by Western blot analysis, correspond-
ing to the pro-MPO and mature MPO forms (Figure 3).
MPO-ANCA binding to the chimeric MPO molecules
To assess whether the MPO light chain harbors target
epitopes, we compared the binding pattern of each serum
sample to the chimerics expressing the murine light chain
(‘lABCD’, ‘lAbcd’, and ‘laBcd’) and the molecules expressing
the human light chain (‘LABCD’, ‘LABcD’, and ‘LAbcd’). No
patient serum demonstrated a consistent binding to the light
chain.
The reactivity of MPO-ANCA sera to the remaining four
chimerics (lAbcd, laBcd, LABcD, and LAbcd) was analyzed.
As we did not express the ‘labcD’ chimeric, we were not
always able to distinguish whether certain samples bound
either or both of the B or D regions or the C and D regions.
Based on the binding pattern of sera from our 14 patients,
sera from 0 patients bound to region A (amino acids (a.a.)
1–108 of heavy chain), sera from six patients bound to region
Mouse: 139 ·····PN········H···························V·M·F·····N····K·P···Q···A·····N····K····A 223
Human: 165 ·····EQ········M···························F·L·Y·····K····P·A···A···E·····T····P····S 249
  Domain:        Light chain 
Mouse: 224 ··F··········ITL·····T················L·······L··········K············ TRN············ 309
Human: 250 ··L··········LDF·····A················V·······V··········A············ PGS············ 335
Domain:     Heavy chain A 
Mouse: 310 ·····G·····D····K···LT·········T·········M···S·······················M··············FV 394
Human: 336 ·····M·····E····N···MS·········Q·········L···N·······················T··············LL 420
Domain: 
Mouse: 395 ········Q··R·····N··K····························A··K····Q···························· 482
Human: 421 ········E··S·····D··R····························T··R····T···························· 508
Domain: Heavy chain B
Mouse: 483 ····N·Q··R·TAA·······K·································V······························ 568
Human: 509 ····D·R··Q·MEP·······R·································A······························ 594
  Domain: Heavy chain C
Mouse: 569 ·················S···E······K··E····A···················EPN····Q····L················· 654
Human: 595 ·················E···Q······R··K····E···················KRK····P····I················· 680
Domain: 
Mouse: 655 ··P····K·······S·····L··················T······S·N···K···T··K·T 719
Human: 681 ··E····M·······Q·····I··················S······N·S···A···A··R·A 745
  Domain: Heavy chain D
Figure 1 | Alignment of human and mouse MPO amino-acid sequences. Identical amino acids are represented by dots. Human–mouse
chimeric molecules were generated by replacing segments of the human or mouse MPO cDNA with homologous segments from the other
species. The five regions used to generate the human-mouse chimerics are delineated by different colors. The seven amino acids at the L–A
junction that are cleaved in the maturation of MPO are not included in this figure.
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Figure 2 | Generation of chimeric molecules. Graphic representa-
tion of the MPO cDNA expression construct showing the Strep-tags
(IBA, Germany) and the restriction enzyme sites used in the
generation of the human–mouse chimeric molecules. Five chimeric
molecules were generated. L/l denotes the MPO light chain. The MPO
heavy chain is ‘divided’ into four regions, denoted as A, B, C, and D.
Capital letters and black bars denote human segments, small letters
and gray bars denote mouse segments.
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B (a.a. 109–237), sera from nine patients bound to region C
(a.a. 238–388), and sera from 10 patients bound to region D
(a.a. 389–469) at some point during the course of disease
(Figure 4). Sera from six patients bound to one region, sera
from six patients reacted to two regions, and sera from two
patients to possibly three regions over time (Table 1). No
individual serum sample bound to more than two regions of
MPO.
In 4 of 10 patients with more than one sample, the
binding pattern never changed over a period of 3–20 months.
In six patients (patient nos. 1, 2, 5, 6, 10, and 11) the binding
pattern changed over a period of 7–27 months. For three
patients (nos. 1, 2, and 11) the target immunodominant
region changed from D to C. For patient no. 6 the target
immunodominant region changed from B to D and for
patient no. 10 it changed from B to C (Table 1). Due to the
small number of patients, we could not correlate the
antibody-binding pattern with changes in clinical levels of
disease activity.
DISCUSSION
Knowledge about the immunodominant target regions
of MPO can provide insight into the MPO-ANCA immune
response. Several studies suggested that the immunodominant
epitopes of MPO are restricted in number and are
conformational in nature,2–4,10 but failed to identify them.
Chimeric molecules have been used to determine the
immunodominant epitopes of several autoantigens in a
preserved three-dimensional configuration.8 This approach
pinpointed seven amino acids in the NC1 domain of the
alpha 3 chain of type IV collagen that are essential to the
structure of the target epitope of anti-glomerular basement
membrane antibodies.9,11 Epitope mapping of proteinase 3
using human–mouse and human proteinase 3–elastase
chimeric antibodies determined a restricted number of target
epitopes, which varied from patient to patient.12 The goal of
this study was to identify the target immunodominant
epitope(s) of MPO. In this respect, our use of recombinant
human MPO limits identification of some target epitopes,
especially those present only on the dimerized holoenzyme.
This limitation is reflected in our ability to analyze the target
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Figure 3 | Immunoblot of recombinant mouse and human MPO
and human–mouse chimeric molecules. This immunoblot shows
the recombinant proteins and chimeric molecules detected by
polyclonal rabbit anti-human MPO antibodies. Proteins analyzed are
native¼ native human MPO, r. human¼ recombinant human MPO; r.
mouse¼ recombinant mouse MPO.
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Figure 4 | Percentage of patients with antibodies to each region
of MPO (some patients bound more than one region, as detailed
in Table 1).
Table 1 | Patient characteristics and pattern of MPO-ANCA binding for each sample tested
Target region: sequential samplesb
Patient Age Gender Diagnosis Time interval (months)a I II III IV V VI VII VIII
1 57 F MPA 7 D C/Dc C
2 59 F WG 17 D C C C
3 36 F WG 16 C C
4 63 M MPA 3 D D D D
5 55 M MPA 16 B&D D/Bc
6 45 F WG 18 B B B D D D D D
7 76 F WG 0 D/Bc
8 75 F MPA 20 C C
9 50 M RENAL 0 C
10 21 F RENAL 24 B B/Dc C/Bc C
11 46 F MPA 27 D D/Bc D/Bc D/Bc D/Bc C C C
12 71 F RENAL 0 D
13 75 F MPA 11 C C
14 78 M MPA 0 B&D
Abbreviations: F, female; M, male; MPA, microscopic polyangiitis; MPO-ANCA, myeloperoxidase-antineutrophil cytoplasmic autoantibodies; renal, pauci-immune necrotizing
glomerulonephritis without extra-renal vasculitis; WG, Wegener’s granulomatosis.
aTime interval in months between the first and last serum sample.
bAntibody target region for each serum sample available from each patient.
cUnable to ascertain if reactivity is to one, the other or both regions of MPO.
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regions of sera from 50% of the patients originally screened
for this study. The recombinant human MPO molecule may
also differ from the native molecule as a result of changes in
folding and post-translational modifications such as glyco-
sylation or the expression of the ‘pro-form’ as opposed to the
‘mature’ MPO molecule.13 Nevertheless, using the observa-
tion that most human MPO-ANCA patient sera bind human
but not mouse recombinant MPO, we were able to define a
limited number of antigenic regions of interest.
In our study, sera from 71% of patients did not bind
recombinant mouse MPO. Similarly, serum from only 1 of 36
(2.7%) patients with MPO-ANCA vasculitis bound rat
MPO.14 These results confirm that MPO-ANCA recognize
epitopes on human MPO that are absent on rat or mouse
MPO.
Several investigators have concluded that the target
epitopes of MPO are conformational in nature by demon-
strating that MPO-ANCA bound only the MPO holoenzyme,
but not the denatured protein.2,10 Using expressed protein
fragments of MPO, researchers have similarly deduced that
the epitopes are conformational in nature and demonstrated
that the immunodominant epitopes are likely on the heavy
chain of MPO.6,15,16 We confirm this observation as all the
patient sera bound to the heavy chain, and none bound to the
light chain. Based on the crystal structure of MPO,17,18 the
three-dimensional model of MPO reveals that, in the dimer
form, the light chain is largely ‘hidden’ in the groove between
the two MPO monomers and is poorly ‘accessible’ to
antibody binding (Figure 5).
In contradistinction with anti-glomerular basement
membrane autoantibodies where the majority of patients
react to a single, well-defined epitope,9 the MPO-ANCA sera
tested in this study most frequently bound epitopes restricted
to the C or D region of the heavy chain. Based on the three-
dimensional model of MPO, these two regions are ‘inter-
twined’ on the same ‘hemisphere’ of the molecule (Figure 4).
Our results corroborate some of the results of Fujii et al.,16
who studied the pattern of reactivity of 20 sera from 20
MPO-ANCA patients against a panel of 10 partially over-
lapping recombinant fragments of MPO. In their study, 53%
of patients bound to the terminal 147 amino acids of the
heavy chain (corresponding to a region encompassing part of
our C region and the entire D region). However, our results
diverge from theirs, in that 84% of their sera bound the first
62 amino acids and 63% the next 68 amino acids near the
amino-terminus of the heavy chain (corresponding to our A
region and a junction of our regions A and B, respectively).
These results most likely derive from the fact that Fujii et al.16
expressed fragments of human MPO which were not
presented in a preserved three-dimensional molecular
structure.
The finding of a restricted number of target epitopes was
previously suggested based on studies using the method of
competition among various antibodies.2–4 Although studies
of competitive binding of antibodies to their target antigen
are helpful in determining the relative number of epitopes,
they generally fail to identify the ‘location’ (target amino
acids) of these epitopes. This general approach is further
hindered by influences of protein–protein interaction, since
the binding of one antibody to MPO may alter the molecule
or block the binding of other antibodies to adjacent epitopes,
for example.4
It is important to note that although we report the
restriction of ANCA reactivity to relatively large regions of
the MPO molecule (C and D regions corresponding to a total
of 230 amino acids), the actual number of amino acids that
differ between the human and mouse molecules within these
regions is much smaller (28 amino acids) (Figure 1). Within
the C and D regions, there are four small regions of marked
heterogeneity between the mouse and human MPO mole-
cules that are separated by long stretches of amino-acid
identity. We will assess whether these non-contiguous
divergent amino acids are important to the structure of the
target epitopes creating MPO chimerics with smaller areas of
differences between the human and mouse molecules.
We tested serial serum samples in 10 of our 14 patients.
Although we observed changes in the antibody-binding
pattern with time in six patients, these changes
were infrequent, occurring once over 3–20 months in
all but one patient. Owing to the relatively small number
of patients in our study, and the inherently variable nature
of ANCA vasculitis,19 we could not determine a clear
correlation between the antibody-binding profile and
specific disease manifestations or levels of activity or changes
thereof. To do so with confidence requires the prospective
– Light chain Heavy chain regions
– A
– B
– C
– D
d
ca
b
Figure 5 | Three-dimensional modeling of MPO. MPO is a 140 kDa
dimer, with each monomer composed of a heavy (59 kDa) and a light
chain (13.5 kDa). This figure shows four views of MPO. (a, b) show two
views of the MPO dimer. (c) shows a ‘profile’ view of the MPO
monomer, and (d) shows the surface of the MPO monomer that faces
the other monomer. The latter view reveals that, in the dimeric form,
the light chain is ‘sandwiched’ in the groove between the two
monomers, and is partially hidden from the surface of the molecule
(based on the MPO structure from National Center for Biotechnology
Information structure 1 DNW).
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analysis of multiple serum samples from a large group of
patients.
In summary, we employed an approach to the epitope
mapping of MPO that preserves its three-dimensional
structure. Our data reveal that MPO-ANCA react to one or
more epitopes on the recombinant human, but not mouse,
MPO molecule. Using our panel of chimeric mouse–human
MPO molecules, we demonstrated a restriction of antibody
reactivity to two intertwined target regions corresponding to
the carboxy-terminus of the heavy chain. We plan to further
pinpoint the target epitopes of MPO-ANCA by replacing
smaller fragments of the mouse or human MPO with
homologous regions from the other species, focusing on the
discrete foci of marked heterogeneity in the amino-acid
sequences between human and mouse at the carboxy-end of
the MPO molecule.
MATERIALS AND METHODS
Patients and sera
Ninety-five archival serum samples from 28 patients with MPO-
ANCA vasculitis were screened for use in this study. Of these, 52
samples from 14 patients were excluded from further analysis due to
lack of binding to the recombinant human MPO (29 samples),
binding to the ‘no-antigen’ control (10 samples) or similar reactivity
to both mouse and human recombinant MPO (13 samples from
eight patients).
Fourteen MPO-ANCA positive patients with microscopic
polyangiitis, Wegener’s granulomatosis or pauci-immune crescentic
glomerulonephritis (age range 21–75 years old; 10 females) provided
43 serum samples (1–8 samples per patient) for testing against our
panel of chimeric molecules (Table 1) collected at various times
during their disease course and stored at 201C. These serum
samples were derived from patients with different and changing
degrees of disease activity, ranging from active vasculitis to
remission on and off immunosuppressive therapy. Thirteen of 14
patients provided at least one serum sample, while having signs of
active vasculitis. Serum samples from 11 healthy volunteers (age
range 21–60 years old; seven females) served as negative controls.
This study was conducted in accordance with the Declaration of
Helsinki Principles with an Institutional Review Board approved
protocol. Informed consent was obtained prior to the blood
collections.
Generation of chimeric molecules
Full-length cDNA for human MPO was provided by Dr William
Nauseef (University of Iowa, Iowa City, IA, USA); cDNA for mouse
MPO was obtained by polymerase chain reaction (PCR) cloning
from RNA isolated from WEHI 3BD cells20 (American Type Culture
Collection, Manassas, VA, USA). Using PCR, a HindIII restriction
site and a Kozac consensus translation initiation sequence were
introduced 50 to the coding sequence (Figure 2). At the 30 end of the
cDNA, we introduced 18 nucleotides encoding an in-frame
StrepTags peptide (IBA, Go¨ttingen, Germany) followed by a stop
codon and an XhoI site. Both the human and murine cDNA for
MPO were cleaved by HindIII/XhoI and subcloned into a pcDNA3
vector (Invitrogen, Leek, The Netherlands).
Six human–mouse chimeric molecules were generated (Figure 2).
In describing the chimeric molecules, we used capital letters to
denote a human segment and lower-case letters to denote a mouse
segment. ‘L’ or ‘l’ denote the MPO light chain. The heavy chain was
‘divided’ into four segments, namely A, B, C, and D (Figures 3, 4a
and b) based on the regions of heterogeneity between the mouse and
human molecules and the presence of convenient restriction enzyme
sites (ApaI and KpnI) usable on both the human and mouse MPO
cDNA. For example, in ‘lAbcd’ only the ‘A’ region of the heavy chain
is of human origin and the other parts originate from the mouse
sequence. The recombinant mouse and human MPO constructs are
referred to as ‘labcd’ and ‘LABCD’, respectively. The L, A, B, C, and
D regions correspond to human a.a. numbers, 165–272, 279–386,
387–516, 517–667, and 668–745, and murine a.a. numbers 139–246,
253–360, 361–490, 491–641, and 642–719, respectively.
The ‘lABCD’ chimeric was created by sequential PCR
technique,21 where the ‘l’ was amplified from the ‘labcd’ and
the ‘ABCD’ part from the ‘LABCD’. The PCR products were
purified, combined, and used as template to allow fusion of the two
products in a second PCR reaction using the forward murine ‘l’
primer and the reverse human ‘D’ primer. The final PCR product
was then cleaved using HindIII/XhoI and inserted into the pcDNA3
vector.
‘lAbcd’ and ‘LAbcd’ were generated from ‘lABCD’ and ‘LABCD’,
respectively. The ‘bcd’ segment was generated by standard PCR
using ‘labcd’ as template, and subcloned into the previously digested
‘lABCD’ and ‘LABCD’ cDNA using restriction enzymes PshAI
(New England Biolabs, Ipswitch, MA, USA) at a.a. 386 and XhoI
(New England Biolabs, Ipswitch, MA, USA) 30 to the MPO coding
sequence (Figure 2).
The ‘laBcd’ chimeric was generated from ‘labcd’ and a newly
generated ‘Bcd’ fragment. Sequential PCR technique was applied to
generate the segment ‘Bcd’. The murine sequence contains an ApaI
site at the ‘a–b’ join that the human sequence lacks. Thus, a new
ApaI site was introduced at the 50 end of ‘B’ during the PCR
generation of the ‘B’ fragment. In a second PCR, the segment ‘cd’
with an ApaI site in the 30 end was generated using the ‘labcd’ as
template. A third PCR used the segments ‘B’ and ‘cd’ as templates to
create ‘Bcd’. The ‘bcd’ fragment was excised from ‘labcd’ using the
ApaI sites and the new ‘Bcd’ was subcloned into the ‘pcDNA3-la’
DNA. This approach was also used to generate the ‘labcD’ chimeric
molecule, using ‘labcd’ as the initial template.
The ‘LABcD’ chimeric was generated using ‘LABCD’ as template.
The restriction enzyme KpnI (New England Biolabs) was utilized to
cut out ‘C’ at a.a. 516 and 667 and replace it by the corresponding
mouse ‘c’ segment, which was isolated after similar Kpn1 digestion.
For each chimera, the final cDNA construct cloned into the
expression vector was sequenced using external and internal
sequencing primers to verify that it was complete and corresponded
to the desired sequence.
Human embryonic kidney 293 cells were cultured in Dulbecco’s
modified Eagle’s medium/F12 medium (Gibco: Invitrogen Corp,
Carlsbad, CA, USA) plus 10% fetal bovine serum (Gibco). For each
construct, 8 105 cells were transfected with 20 mg of plasmid by
electroporation (Bio-Rad, Hercules, CA, USA) at 200 V and 960mF.
Geneticins (400 mg/ml) (Gibco)-resistant cell clones producing
recombinant protein, as determined by enzyme-linked immunosor-
bent assay, were expanded and transferred to serum-free Dulbecco’s
modified Eagle’s medium/F12 1 week prior to collection of cell
culture supernatant.
Purification of recombinant proteins
Proteins from cell culture supernatant were precipitated using
ammonium sulfate at 41C in the presence of protease inhibitors. The
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suspension was centrifuged at 18 600 g for 30 min. The pellet was
dissolved in and dialyzed against the sample buffer (50 mM Tris
buffer, 0.02% azide, pH 7.5). The samples were run through an
anion exchange column (UnoQ, Bio-Rad) and the flow-throughs
containing the MPO protein were collected and concentrated using
ultrafiltration devices (Vivaspin, VivaScience). The purity of the
recombinant proteins was determined by analysis of silver-stained
sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels and
by Western blot analysis. Protein concentration was determined by
measuring the absorbance at 280 nm and confirmed by comparing
intensities of recombinant protein bands with a known amount of
purified human MPO (Calbiochem) on silver-stained sodium
dodecyl sulfate-polyacrylamide gel electrophoresis gels.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
and immunoblotting
A 4–15% Tris-HCl gel (Bio-Rad) was run in Laemmli buffer system
at 100 V for 90 min and stained using a Silver Stain Plus kit (Bio-
Rad). For immunoblotting, proteins were transferred to a
nitrocellulose membrane (Schleicher and Schuell, Keene, NH,
USA) (100 V for 60 min). The membranes were blocked with 10%
non-fat milk in Tris-buffered salineþ 0.05% Tween and then
incubated overnight at 41C with a rabbit anti-human MPO antibody
diluted 1:5000. The membranes were washed and incubated with a
horseradish peroxidase-conjugated goat anti-rabbit IgG (Chemicon,
Temecula, CA, USA) for 1 h; proteins were detected with Super-
Signal West Pico Chemiluminescent Substrate (Pierce, Rockford, IL,
USA).
Capture enzyme-linked immunosorbent assay of recombi-
nant MPO proteins
StrepTactins-coated plates (IBA, Germany) were coated overnight
at 41C with recombinant human and mouse MPO and chimeric
molecules at 0.1 mg/well, the saturation concentration for the
StrepTactins plates. The plates were washed and blocked with fish
gelatin buffer (2 g/l in Tris-buffered salineþ 0.05% Tween) for 1 h at
room temperature. MPO-ANCA sera, diluted 1:100 in fish gelatin
buffer, were incubated for 3 h at room temperature. Polyclonal
rabbit anti-human MPO antibody (1:5000 dilution) served as a
positive control. Sera from healthy donors (diluted 1:100) served as
negative controls. Secondary antibodies, alkaline phosphatase-
conjugated goat anti-rabbit IgG (Pierce) and goat anti-human IgG
(Pierce) (diluted 1:5000) were added for 1 h at room temperature.
Bound antibodies were detected with an Alkaline Phosphatase
Substrate Kit (Bio-Rad). Absorption was measured spectrophoto-
metrically at 405 nm after 1 h. All assays were carried out in
duplicate.
Data analysis
The reactivity of normal sera to the various recombinant proteins
varied substantially. For this reason, we first normalized the
reactivity of each serum sample against the ‘background’ by testing
each serum sample against the blocking buffer as a no-antigen
control (ODbackground) according to the following equation:
X ¼ ODchimeric  ODbackground
ODchimeric
ð1Þ
Equation (1) was used to calculate the reactivity of each sample
to each recombinant molecule. The reactivity of 11 normal sera
against each chimeric molecule was also determined using Equation
(1). For the reactivity of a serum sample to a recombinant molecule
to be considered positive, it had to be greater than the averageþ 2
s.d. of the normal sera for that molecule using Equation (1).
In order to compare the reactivity of a serum sample to the
various chimeric molecules, we normalized its binding to each
chimeric molecule relative to its binding to the recombinant human
MPO according to Equation (2):
X ¼
ODchimericODbackground
ODchimeric
ODrec:humanMPOODbackground
ODrec:humanMPO
ð2Þ
We assumed that the maximal binding of a serum sample would
be to the recombinant human MPO. Thus, if the reactivities of a
serum sample to the chimeric molecule and recombinant human
MPO are the same, the ratio is 1. A ratio of 0.5 would indicate a 50%
loss of reactivity to the chimeric molecule compared to the
recombinant human MPO. We used a ratio 40.5 as the threshold
for determining the substantial preservation of binding to the
chimeric molecule when compared to that of the recombinant
human MPO.
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